1
项与 Anti-BCMA CAR-NK(Shahid Beheshti University of Medical Sciences) 相关的临床试验Determining Safety and Maximum Tolerated Dose (MTD) of Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma
Immunotherapy has shown promise in the treatment of hematological malignancies, including multiple myeloma. One approach is CAR-NK cell therapy, which involves genetically modifying natural killer (NK) cells to target specific cancer antigens. While CAR-NK therapy offers advantages over CAR-T therapy, such as reduced immune system reactions and lower production time and cost, challenges remain in terms of antitumor efficacy and the tumor microenvironment. Preclinical and early clinical studies have targeted various antigens, including BCMA, with CAR-NK cells in multiple myeloma. To further investigate the potential of BCMA-targeted CAR-NK cell therapy, this study aims to evaluate its safety and determine the maximum tolerated dose (MTD) in patients who have not responded to standard therapy.
100 项与 Anti-BCMA CAR-NK(Shahid Beheshti University of Medical Sciences) 相关的临床结果
100 项与 Anti-BCMA CAR-NK(Shahid Beheshti University of Medical Sciences) 相关的转化医学
100 项与 Anti-BCMA CAR-NK(Shahid Beheshti University of Medical Sciences) 相关的专利(医药)
100 项与 Anti-BCMA CAR-NK(Shahid Beheshti University of Medical Sciences) 相关的药物交易